Alex Matter

TL;DR: This work describes how this drug discovery programme led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.

TL;DR: An association between PKC inhibition and anti‐proliferative and anti-tumor activity is suggested and staurosporine and CGP 41 251 exerted growth inhibition in the human bladder carcinoma line T‐24, human promyelocytic leukemia line HL‐60 and bovine corneal endothelial cells at concentrations which correlated well with in vitroPKC inhibition.

TL;DR: A novel potent, orally available PORCN inhibitor, ETC-1922159, that blocks the secretion and activity of all Wnts is developed that is remarkably effective in treating RSPO-translocation bearing colorectal cancer patient-derived xenografts.

TL;DR: Separate primary and validating clinical studies concur that tumor VEGF level is the most important prognostic parameter among several markers of tumor angiogenesis and proteolysis.

TL;DR: The simultaneous use on mouse lymphoid suspensions of heterologous antisera directed against thymus-derived (T) cell mouse-specific lymphocyte antigen and brain-associated theta antigen and MBLA surface antigens allowed direct proof of the different specificity of these antisona by double immunofluorescence (IF) staining with selective visualization of fluorochromes.